AI in Biotechnology Market Size & Growth Forecast to 2035

AI in Biotechnology Market by Function (Drug Design & Optimization, Biomarker, SAR; Clinical Trial Design, Data Assessment, RWE, Inventory, Supply Chain, Logistics; Launch, Pricing, Patient Engagement, Adverse Events) and End User - Global Forecast to 2035

USD USD 22.72 Billion

MARKET SIZE, 2035

CAGR 18.5%

(2025-2035)

397

REPORT PAGES

471

MARKET TABLES

OVERVIEW

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The AI in biotechnology market size is projected to reach USD 22.72 billion by 2035, from USD 4.16 billion in 2025, at a CAGR of 18.5% during the forecast period. This growth is primarily driven by the increasing adoption of AI for drug discovery, precision medicine, and genomics research, coupled with the rising demand for accelerated biopharmaceutical development. The integration of ML algorithms, predictive analytics, and automation tools into biotechnology workflows enhances research efficiency, improves accuracy in biomarker identification, and optimizes therapeutic development. The convergence of AI with cloud computing and big data platforms further supports large-scale data analysis and decision-making, fueling market expansion.

KEY TAKEAWAYS

BY REGION

The North American AI in biotechnology market accounted for a 42.6% revenue share in 2024.
BY OFFERING

By offering, the end-to-end solutions segment is set to register the highest CAGR of 19.9%.
BY FUNCTION

By function, the research & development segment is projected to grow at the highest rate from 2025 to 2035.
BY DEPLOYMENT MODE

By deployment mode, the cloud-based segment is poised to dominate the market.
BY END USER

By end user, pharmaceutical companies accounted for the largest share, 36.2%, in 2024.
COMPETITIVE LANDSCAPE

NVIDIA, Illumina, Inc., and Recursion are key leaders in the global AI in biotechnology market, recognized for their extensive product portfolios, robust data integration capabilities, and strong presence across healthcare ecosystems.

The AI in biotechnology market is steadily expanding, driven by growing investments in digital transformation and the increasing focus on data-driven drug discovery, genomics, and precision medicine in the US and EU. Advances in machine learning, predictive analytics, and automation are enhancing research efficiency, biomarker identification, and therapeutic development. Moreover, strategic collaborations between biotech firms, AI solution providers, and research institutions are fostering innovation and enabling more integrated, scalable, and intelligent biotechnology workflows.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The impact on consumers’ businesses in the AI in biotechnology market stems from evolving research priorities and technological advancements. Pharmaceutical companies, biotechnology firms, and research institutes are the primary end users, and their adoption needs drive AI implementation. Shifts in these trends or disruptions, such as increasing demand for AI-driven drug discovery, predictive analytics, or automation in genomics and precision medicine, directly influence end-user efficiency and productivity, thereby affecting the financial performance of AI solution providers in the biotechnology sector.

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers

Impact
Level

Rising adoption of AI in precision medicine
Growing cross-industry collaborations and partnerships

RESTRAINTS

Impact
Level

High implementation costs of AI limit adoption in biotechnology, especially for SMEs and emerging economies
Data privacy risks and compliance challenges for AI in biotechnology

OPPORTUNITIES

Impact
Level

Surge in biotechnology investments enhances opportunities for AI to accelerate drug discovery innovations
Innovation across healthcare, agriculture, and environmental science for global growth

CHALLENGES

Impact
Level

Data quality and interpretability issues that hinder AI integration and trustworthiness
AI deployment in biotechnology hindered by talent shortages and evolving regulatory challenges

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Rising adoption of AI in precision medicine

The rising adoption of AI in precision medicine is a key driver of the AI in biotechnology market. By integrating genomic, clinical, pharmaceutical, and lifestyle data, AI enables early disease detection and the development of personalized, effective treatments. AI algorithms can model synthetic patient populations, predict drug responses, and uncover complex interactions between genetics, microbiomes, and environmental factors. These capabilities enhance research accuracy, treatment efficacy, and healthcare efficiency, positioning AI as a transformative force in precision medicine.

Restraint: High implementation costs of AI limit adoption in biotechnology, especially for SMEs and emerging economies

High implementation and maintenance costs remain a major restraint on AI adoption in biotechnology, particularly for SMEs and organizations in emerging economies. Expenses related to licensing, subscriptions, and data management can range from thousands to millions of dollars, making advanced AI solutions financially out of reach for smaller players. Limited IT budgets and prioritization of medical equipment over digital infrastructure further hinder adoption, restricting broader access to AI-driven insights and innovations in the biotechnology sector.

Opportunity: Surge in biotechnology investments enhances opportunities for AI to accelerate drug discovery innovations

The surge in biotechnology investments presents significant opportunities for AI to accelerate drug discovery and innovation. The US, a major biotechnology hub with more than 2,000 private and public companies and 3,429 biotechnology businesses as of 2023 (IBISWorld), is driving this growth. As biotech firms expand, increased funding supports advanced research and the development of novel biopharmaceuticals. AI integration further enhances efficiency in target identification, drug design, and clinical trials, fostering faster and more cost-effective therapeutic innovations.

Challenge: Data quality and interpretability issues that hinder AI integration and trustworthiness

Data quality and interpretability remain major challenges hindering AI integration in biotechnology. Though biotech research produces vast datasets, they are often fragmented and lack standardization, limiting AI’s ability to generate reliable insights. Moreover, the “black box” nature of advanced AI models raises concerns about transparency and trust, particularly in drug discovery and precision medicine. According to the Biocom Institute, over 70% of biotech professionals express concerns about the ethical and interpretability issues of AI, underscoring the need for better data curation and explainable AI systems.

AI in Biotechnology Market: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY	USE CASE DESCRIPTION	BENEFITS
	Provides GPU-accelerated AI platforms for genomics, bioinformatics, and drug discovery	Drives research, boosts scalability, and accelerates drug discovery
	Uses AI to enhance sequencing data analysis and genome interpretation	Improves accuracy, enables faster insights, and supports precision medicine
	Combines AI, automation, and imaging for large-scale biological analysis	Enables faster discovery, target identification, and efficiency gains
	Uses AI and physics-based modeling for virtual screening and drug design	Improves prediction accuracy and streamlines compound optimization
	AI-enabled biomedical knowledge graph for target identification, drug repurposing, and clinical trial prediction	Improved discovery of therapeutic targets, accelerated pipeline development, and increased efficiency in translational research

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The AI in biotechnology market ecosystem comprises key players such as NVIDIA (US), Illumina, Inc. (US), Recursion (US), Schrödinger, Inc. (US), and BenevolentAI (UK), which provide advanced AI-driven platforms for drug discovery, genomics analysis, and precision medicine. These companies leverage ML, predictive analytics, and cloud-based solutions to enhance research accuracy, accelerate therapeutic development, and optimize decision-making. End users, including pharmaceutical companies, biotechnology firms, healthcare providers, and CROs, adopt these technologies to improve R&D efficiency, reduce costs, and drive innovation. Collaboration among technology providers, life science organizations, and research institutions continues to strengthen the AI-enabled biotechnology ecosystem and advance personalized healthcare.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

AI in Biotechnology Market, by Offering

Based on offering, the AI in biotechnology market comprises end-to-end solutions, niche solutions, technologies, and services. The end-to-end solutions segment accounted for the largest share of the market. This growth is attributed to the rising demand for integrated platforms that combine data management, analytics, and automation across the entire biotechnology workflow. These solutions enable seamless collaboration, streamline drug discovery and genomics research, and improve decision-making through real-time insights, making them increasingly preferred by large pharmaceutical and biotechnology companies.

AI in Biotechnology Market, by Function

Based on function, the AI in biotechnology market is segmented into research & development, regulatory compliance, manufacturing & supply chain, launch & commercial, post-marketing surveillance & patient support, and corporate. The research & development segment accounted for the largest share of the market. This is due to the growing use of AI in drug discovery, genomics, and biomarker identification, which significantly accelerates research timelines and enhances accuracy. AI-driven predictive modeling and data analytics also help reduce costs, optimize clinical trial design, and improve the success rate of new drug candidates.

AI in Biotechnology Market, by Deployment Mode

Based on deployment mode, the market is bifurcated into cloud-based and on-premise. The cloud-based segment accounted for the largest share of the AI in biotechnology market. This is attributed to the growing preference for scalable, flexible, and cost-efficient solutions that enable real-time data access and collaboration across global research teams. Cloud platforms facilitate seamless integration of AI tools, advanced analytics, and large-scale data storage, supporting faster drug discovery and genomics research while reducing infrastructure and maintenance costs for end users.

AI in Biotechnology Market, by End User

Based on end users, the market is segmented into pharmaceutical companies, biotechnology companies, research institutes & labs, healthcare providers, and contract research organizations (CROs). Pharmaceutical companies accounted for the largest share of the AI in biotechnology market. This is due to their extensive investment in AI-driven drug discovery, precision medicine, and clinical trial optimization, which helps accelerate R&D timelines and reduce costs. The integration of AI enables these companies to improve decision-making, enhance the accuracy of therapeutic development, and maintain a competitive edge in an increasingly data-driven biopharma landscape.

REGION

Asia Pacific to be fastest-growing region in global AI in biotechnology market during forecast period

Asia Pacific is projected to be the fastest-growing region in the global AI in biotechnology market during the forecast period. This is due to increasing investments in biotechnology research, the rising adoption of AI-driven drug discovery and precision medicine, and supportive government initiatives in countries such as China, India, and Japan. The region’s growing number of biotech startups, expanding healthcare infrastructure, and focus on innovation are driving demand for advanced AI solutions, fostering rapid market growth.

AI in Biotechnology Market: COMPANY EVALUATION MATRIX

In the AI in biotechnology market matrix, NVIDIA (Star) leads with a strong market presence and a comprehensive AI platform portfolio, driven by high-performance computing, machine learning frameworks, and scalable cloud-based solutions for drug discovery, genomics, and precision medicine. The company’s focus on accelerating AI-driven research, predictive modeling, and large-scale data analytics reinforces its dominant position across pharmaceutical, biotechnology, and healthcare organizations globally. Xtalpi Inc. (Emerging Leader) is gaining traction with innovative AI-powered drug design and predictive chemistry solutions, strengthening its position through niche capabilities and industry-specific offerings that address evolving needs in biopharmaceutical R&D.

AI in Biotechnology Market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC	DETAILS
Market Size, 2024 (Value)	USD 3.51 Billion
Market Forecast, 2035 (Value)	USD 22.72 Billion
Growth Rate	CAGR of 18.5% from 2025 to 2035
Years Considered	2024–2035
Base Year	2024
Forecast Period	2025–2035
Units Considered	Value (USD Million/Billion)
Report Coverage	Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Segments Covered	By Offering: End-to-end Solutions Niche Solutions Technologies Services By Function: Research & Development Regulatory Compliance Manufacturing & Supply Chain Launch & Commercial Post-Market Surveillance & Patient Support Corporate By Deployment Mode: Cloud-based On-premise By End User: Pharmaceutical Companies Biotechnology Companies Research Institutes & Labs Healthcare Providers Contract Research Organizations (CROs)
Regions Covered	North America, Europe, Asia Pacific, Latin America, Middle East & Africa

WHAT IS IN IT FOR YOU: AI in Biotechnology Market REPORT CONTENT GUIDE

AI in Biotechnology Market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST	CUSTOMIZATION DELIVERED	VALUE ADDS
Competitive Landscape Mapping	Profiles and market share of leading AI vendors in biotechnology (including Insilico Medicine, BenevolentAI, Recursion, Xtalpi), covering AI platforms, data capabilities, drug discovery pipelines, partnerships, AI model types (ML, DL, NLP), and integration with omics data, EHRs, and clinical trials	Enables benchmarking of AI capabilities and partnerships, identification of competitive positioning, assessment of market share by application area (drug discovery, diagnostics), and strategic alliances
Market Entry & Growth Strategy	Regional and segment-level opportunity assessment (e.g., drug discovery, synthetic biology, precision medicine), analysis of funding trends, startup ecosystem, regulatory support for AI applications, and partnership ecosystems (pharma, academia, tech firms)	Accelerates go-to-market planning, de-risks market entry, and supports commercialization, localization, and long-term growth strategies tailored to biotech sub-sectors
Regulatory & Operational Risk Analysis	Analysis of AI/ML regulations in biotech across key geographies (FDA’s AI/ML-based SaMD framework, EU AI Act), data privacy laws (HIPAA, GDPR), explainability and validation challenges, and ethical AI deployment in life sciences	Supports regulatory readiness, reduces compliance risks, and improves trust and adoption of AI technologies by healthcare providers, biotech firms, and regulatory bodies
Technology Adoption Trends	Insights into adoption of AI in biotech R&D, clinical trials, manufacturing, and personalized medicine; analysis of drivers like cloud infrastructure, data interoperability, real-world data, and AI-driven collaboration models	Informs innovation strategy, drives targeted investments, and guides product development aligned with evolving AI readiness in biotech institutions

RECENT DEVELOPMENTS

January 2025 : NVIDIA introduced Project DIGITS, a personal AI supercomputer powered by the new NVIDIA GB10 Grace Blackwell Superchip. Offering 1 petaflop of AI performance, the system would enable researchers, developers, and students to run models with up to 200 billion parameters on a desktop. Designed for energy efficiency, it supports prototyping, fine-tuning, and deployment of AI applications seamlessly across local systems, cloud, and data centers.
January 2025 : Illumina launched a pilot proteomics program to analyze 50,000 UK Biobank samples in collaboration with deCODE Genetics, Standard BioTools, Tecan, GSK, Johnson & Johnson, and Novartis. The program utilized the upcoming Illumina Protein Prep solution to generate high-quality proteomics data, advancing biological insights and facilitating biomarker discovery for conditions like cancer and cardiovascular disease.
July 2024 : Schrödinger, Inc. initiated an expansion of its computational platform to predict toxicology risks early in drug discovery. This initiative, funded by a USD 10 million grant from the Bill & Melinda Gates Foundation, aims to enhance drug candidate properties while reducing the risks of development failure associated with off-target protein binding.

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE

PAGE NO

INTRODUCTION

RESEARCH METHODOLOGY

EXECUTIVE SUMMARY

PREMIUM INSIGHTS

MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS

DRIVERS

- Growing cross-industry collaborations and partnerships

- Growing need to reduce time and cost of drug discovery and development

- Rising adoption of AI in precision medicine

- Improving computing power and declining hardware cost

RESTRAINTS

- High implementation costs of AI limit adoption in biotechnology, especially for SMEs and emerging economies

- Data privacy risks and compliance challenges for AI in biotechnology

OPPORTUNITIES

- Integrating AI and big data in precision medicine for biotechnology advancement

- Surge in biotechnology investments enhances opportunities for AI to accelerate drug discovery innovations

- Innovation across healthcare, agriculture, and environmental science for global growth

CHALLENGES

- Data quality and interpretability issues that hinder AI integration and trustworthiness

- AI deployment in biotechnology hindered by talent shortages and evolving regulatory challenges
5.3 ECOSYSTEM ANALYSIS
5.4 CASE STUDY ANALYSIS

LEVERAGED NVIDIA DGX CLOUD FOR RAPID TRAINING OF PROTEIN MODELS

IMPLEMENTED END-TO-END NGS WORKFLOW FOR EFFICIENT GENETIC VARIANT DETECTION

ACCELERATED DRUG DISCOVERY WITH GENERATIVE AI AND STREAMLINED WORKFLOWS
5.5 VALUE CHAIN ANALYSIS
5.6 PORTER'S FIVE FORCES ANALYSIS

BARGAINING POWER OF SUPPLIERS

BARGAINING POWER OF BUYERS

THREAT OF SUBSTITUTES

THREAT OF NEW ENTRANTS

INTENSITY OF COMPETITIVE RIVALRY
5.7 REGULATORY ANALYSIS

REGULATORY LANDSCAPE

- North America

- Europe

- Asia Pacific

- Latin America

- Middle East & Africa

REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.8 PATENT ANALYSIS

PATENT PUBLICATION TRENDS FOR AI IN BIOTECHNOLOGY

JURISDICTION AND TOP APPLICANT ANALYSIS
5.9 TECHNOLOGY ANALYSIS

KEY TECHNOLOGIES

- Natural language processing (NLP)

- Predictive analytics

COMPLEMENTARY TECHNOLOGIES

- Cloud computing

- Big data analytics
5.10 INDUSTRY TRENDS

EVOLUTION OF AI IN BIOTECHNOLOGY

COMPUTER-AIDED DRUG DESIGN AND AI
5.11 PRICING ANALYSIS

INDICATIVE PRICING ANALYSIS, BY DRUG DISCOVERY PROCESS

AVERAGE SELLING PRICE, BY REGION (QUALITATIVE)
5.12 KEY CONFERENCES & EVENTS, 2025–2026
5.13 KEY STAKEHOLDERS & BUYING CRITERIA

BUYING CRITERIA
5.14 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.15 END-USER ANALYSIS

UNMET NEEDS

END-USER EXPECTATIONS
5.16 INVESTMENT & FUNDING SCENARIO
5.17 IMPACT OF AI/GEN AI ON AI IN BIOTECHNOLOGY MARKET

KEY USE CASES

CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION

- Case study: Accelerated biomarker discovery and clinical trial optimization

IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS

- Drug discovery and development market

- Genomics and bioinformatics market

- Medical imaging & diagnostics market

USER READINESS & IMPACT ASSESSMENT

- User readiness

- Impact assessment

AI IN BIOTECHNOLOGY MARKET, BY OFFERING

104

6.1 INTRODUCTION
6.2 END-TO-END SOLUTIONS

GROWING USE OF ADVANCED ALGORITHMS TO IMPROVE PRECISION AND EFFICIENCY TO BOOST MARKET GROWTH
6.3 NICHE SOLUTIONS

ABILITY OF NICHE SOLUTIONS TO ADDRESS SPECIFIC CHALLENGES WITHIN DRUG DISCOVERY TO SUPPORT ADOPTION
6.4 TECHNOLOGIES

ABILITY OF TECHNOLOGIES TO ENHANCE DRUG DISCOVERY, PERSONALIZED MEDICINE, AND DATA ANALYTICS TO FUEL GROWTH
6.5 SERVICES

CONSULTING SERVICES

- Increasing efficiency of research processes and cost savings to boost adoption of consulting services

IMPLEMENTATION SERVICES & ONGOING IT SUPPORT

- Increasing precision and efficiency in IT support services to boost demand

TRAINING & EDUCATION SERVICES

- Need for skilled talent to drive market growth

POST-SALES & MAINTENANCE SERVICES

- Complexity of AI systems and need for improvement in AI algorithms to boost market

AI IN BIOTECHNOLOGY MARKET, BY FUNCTION

113

7.1 INTRODUCTION
7.2 RESEARCH & DEVELOPMENT

DRUG DISCOVERY

- Molecular design & optimization

- Biomarker discovery

- Structure-activity relationship (SAR) modeling

CLINICAL DEVELOPMENT

- Trial design

- Site selection

- Recruitment

- Clinical data assessment

- Predictive toxicity & risk monitoring

- Monitoring & drug adherence

- Real-world evidence (RWE) analysis
7.3 REGULATORY COMPLIANCE

ABILITY OF AI TO ENSURE REGULATORY COMPLIANCE IN CLINICAL TRIALS TO SUPPORT GROWTH
7.4 MANUFACTURING & SUPPLY CHAIN

SUPPLY CHAIN PLANNING

- Increasing demand for real-time data analytics to accelerate market growth

INVENTORY MANAGEMENT

- Automating stock tracking and replenishment with advanced analytics to fuel growth

LOGISTICS OPTIMIZATION

- Ability of AI to drive collaboration and transparency in biotechnology logistics to aid growth

DEMAND FORECASTING

- Ability to integrate data for reliable demand forecasts to fuel growth

PREDICTIVE MAINTENANCE

- Boosting equipment reliability with AI-powered predictive maintenance to drive demand

OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS
7.5 LAUNCH & COMMERCIAL

LAUNCH COORDINATION

- Growing product launch success rates through predictive analytics to boost adoption

PATIENT ENGAGEMENT

- Advantages such as real-time patient feedback for better health outcomes to support growth

MARKETING OPERATIONS

- Enhanced marketing performance with AI to boost market

PREDICTIVE PRICING

- Ability of AI to enhance pricing accuracy to drive adoption
7.6 POST-MARKETING SURVEILLANCE & PATIENT SUPPORT

MEDICATION ADHERENCE

- Growing demand for personalized healthcare to drive market

ADVERSE EVENT REPORTING

- Advantages such as faster post-market surveillance and enhanced drug safety to drive demand

PATIENT MONITORING

- Rise of remote healthcare solutions to boost demand

COMPLIANCE MONITORING

- Increasing complexity of regulatory requirements to drive adoption

PATIENT SUPPORT PROGRAMS

- Growing interest in patient-centered care to support growth
7.7 CORPORATE

RISK MANAGEMENT

- Rising expenditure for drug development to support growth

COMPLIANCE MONITORING

- Strict guidelines from bodies to aid growth

SALES FORCE OPTIMIZATION

- Need for data-driven decision-making to boost adoption of sales force optimization

OTHER CORPORATE FUNCTIONS

AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE

144

8.1 INTRODUCTION
8.2 CLOUD-BASED SOLUTIONS

PUBLIC CLOUD

- Need to reduce dependency on expensive on-premise infrastructure to boost demand

PRIVATE CLOUD

- Need for enhanced security and data protection to drive market growth

MULTI-CLOUD

- Enhanced flexibility & cost optimization to support market growth

HYBRID CLOUD

- Cost efficiency and flexibility of hybrid cloud to fuel growth
8.3 ON-PREMISE SOLUTIONS

ADVANTAGES SUCH AS DATA SECURITY AND PRIVACY AND COMPLIANCE WITH REGULATIONS TO FAVOR GROWTH

AI IN BIOTECHNOLOGY MARKET, BY END USER

152

9.1 INTRODUCTION
9.2 PHARMACEUTICAL COMPANIES

INNOVATION AND EFFICIENCY ASSOCIATED WITH AI INTEGRATION IN DRUG DISCOVERY & DEVELOPMENT TO BOOST ADOPTION
9.3 BIOTECHNOLOGY COMPANIES

ABILITY OF AI-DRIVEN INNOVATIONS TO ACCELERATE PERSONALIZED MEDICINE AND DRUG DISCOVERY TO SUPPORT GROWTH
9.4 RESEARCH INSTITUTES & LABS

STRATEGIC INVESTMENTS AND COLLABORATIONS TO PROPEL AI ADVANCEMENTS IN RESEARCH INSTITUTES AND LABS
9.5 HEALTHCARE PROVIDERS

IMPROVED PATIENT OUTCOMES TO SUPPORT ADOPTION
9.6 CONTRACT RESEARCH ORGANIZATIONS (CROS)

ABILITY OF AI TECHNOLOGIES TO ACCELERATE CLINICAL TRIALS AND IMPROVE PATIENT RECRUITMENT TO FUEL GROWTH

AI IN BIOTECHNOLOGY MARKET, BY REGION

159

10.1 INTRODUCTION
10.2 NORTH AMERICA

MACROECONOMIC OUTLOOK FOR NORTH AMERICA

US

- Increasing investments and partnerships to drive market

CANADA

- Availability of advanced facilities and shorter approval times for drug candidates to drive market
10.3 EUROPE

MACROECONOMIC OUTLOOK FOR EUROPE

GERMANY

- Increased funding in start-ups to drive uptake of AI in biotechnology

UK

- Increasing investments and government fund allocations to drive market

FRANCE

- Government initiatives in France to support market growth

ITALY

- Growing investments to create opportunities for market growth

SPAIN

- Increasing need for personalized medicine and data-driven healthcare to increase adoption rate in market

REST OF EUROPE
10.4 ASIA PACIFIC

MACROECONOMIC OUTLOOK FOR ASIA PACIFIC

JAPAN

- Accelerating AI-driven drug discovery and biotechnology innovation to drive market in Japan

CHINA

- Rising foreign investments to drive market in China

INDIA

- Increasing number of start-ups and support from government to propel market

SOUTH KOREA

- Significant advances in AI integration for R&D to fuel growth

REST OF ASIA PACIFIC
10.5 LATIN AMERICA

MACROECONOMIC OUTLOOK FOR LATIN AMERICA

BRAZIL

- Funding of biotech companies to drive market in Brazil

MEXICO

- Investment inflows and strengthening AI-related education to drive market in Mexico

REST OF LATIN AMERICA
10.6 MIDDLE EAST & AFRICA

MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

GCC COUNTRIES

- Increase in healthcare investments to support market growth

REST OF MIDDLE EAST & AFRICA

COMPETITIVE LANDSCAPE

302

11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN

OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN AI IN BIOTECHNOLOGY MARKET
11.3 REVENUE ANALYSIS, 2019–2023
11.4 MARKET SHARE ANALYSIS, 2023

RANKING OF KEY MARKET PLAYERS
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023

STARS

EMERGING LEADERS

PERVASIVE PLAYERS

PARTICIPANTS

COMPANY FOOTPRINT: KEY PLAYERS, 2023

- Company footprint

- Component footprint

- Application footprint

- End-user footprint

- Region footprint
11.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023

PROGRESSIVE COMPANIES

RESPONSIVE COMPANIES

DYNAMIC COMPANIES

STARTING BLOCKS

COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
11.7 COMPANY VALUATION & FINANCIAL METRICS
11.8 BRAND/PRODUCT COMPARISON
11.9 COMPETITIVE SCENARIO

PRODUCT LAUNCHES & UPGRADES

DEALS

EXPANSIONS

COMPANY PROFILES

325

12.1 KEY PLAYERS

NVIDIA CORPORATION

- Business overview

- Products offered

- Recent developments

- MnM view

ILLUMINA, INC.

- Business overview

- Products offered

- Recent developments

- MnM view

EXSCIENTIA

- Business overview

- Products offered

- Recent developments

- MnM view

SCHRÖDINGER, INC.

- Business overview

- Products offered

- Recent developments

RECURSION PHARMACEUTICALS, INC.

- Business overview

- Products offered

- Recent developments

SOPHIA GENETICS

- Business overview

- Products offered

- Recent developments

PREDICTIVE ONCOLOGY

- Business overview

- Products offered

- Recent developments

BENEVOLENTAI

- Business overview

- Products offered

- Recent developments

EUROFINS DISCOVERY

- Business overview

- Products offered

- Recent developments

XTALPI INC.

- Business overview

- Products offered

- Recent developments

DNANEXUS, INC.

- Business overview

- Products offered

- Recent developments

NUMEDII, INC.

- Business overview

- Products offered

BPGBIO, INC.

- Business overview

- Products offered

- Recent developments

IKTOS

- Business overview

- Products offered

- Recent developments

INSILICO MEDICINE

- Business overview

- Products offered

- Recent developments

LOGICA (CHARLES RIVER + VALO HEALTH)

- Business overview

- Products offered

- Recent developments

AMERICAN CHEMICAL SOCIETY

- Business overview

- Products offered

AGANITHA AI INC.

- Business overview

- Products offered

- Recent developments
12.2 START-UP/SME PLAYERS

VERISIM LIFE

VALO HEALTH

TEMPUS AI, INC.

LIFEBIT BIOTECH LTD.

GENOOX

DATA4CURE, INC.

DEEP GENOMICS

APPENDIX

386

13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS

LIST OF TABLES

TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
TABLE 2 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS IN AI IN BIOTECHNOLOGY MARKET (2021−2025)
TABLE 3 AI IN BIOTECHNOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 4 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 5 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 7 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 8 LIST OF PATENTS/PATENT APPLICATIONS IN AI IN BIOTECHNOLOGY MARKET, 2021–2024
TABLE 9 AI IN BIOTECHNOLOGY MARKET: INDICATIVE PRICING, BY DRUG DISCOVERY PROCESS
TABLE 10 AI IN BIOTECHNOLOGY MARKET: KEY CONFERENCES & EVENTS, 2025–2026
TABLE 11 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS (%)
TABLE 12 KEY BUYING CRITERIA FOR TOP 3 END USERS
TABLE 13 UNMET NEEDS IN AI IN BIOTECHNOLOGY MARKET
TABLE 14 END-USER EXPECTATIONS IN AI IN BIOTECHNOLOGY MARKET
TABLE 15 AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 16 AI IN BIOTECHNOLOGY MARKET FOR END-TO-END SOLUTIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 17 AI IN BIOTECHNOLOGY MARKET FOR NICHE SOLUTIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 18 AI IN BIOTECHNOLOGY MARKET FOR TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 19 AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 20 AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY REGION, 2022–2029 (USD MILLION)
TABLE 21 AI IN BIOTECHNOLOGY MARKET FOR CONSULTING SERVICES, BY REGION, 2022–2029 (USD MILLION)
TABLE 22 AI IN BIOTECHNOLOGY MARKET FOR IMPLEMENTATION SERVICES & ONGOING IT SUPPORT, BY REGION, 2022–2029 (USD MILLION)
TABLE 23 AI IN BIOTECHNOLOGY MARKET FOR TRAINING & EDUCATION SERVICES, BY REGION, 2022–2029 (USD MILLION)
TABLE 24 AI IN BIOTECHNOLOGY MARKET FOR POST-SALES & MAINTENANCE SERVICES, BY REGION, 2022–2029 (USD MILLION)
TABLE 25 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
TABLE 26 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 27 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS,BY REGION, 2022–2029 (USD MILLION)
TABLE 28 EXAMPLES OF AI TOOLS USED IN DRUG DISCOVERY
TABLE 29 AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 30 AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY REGION, 2022–2029 (USD MILLION)
TABLE 31 AI IN BIOTECHNOLOGY MARKET FOR MOLECULAR DESIGN & OPTIMIZATION, BY REGION, 2022–2029 (USD MILLION)
TABLE 32 AI IN BIOTECHNOLOGY MARKET FOR BIOMARKER DISCOVERY, BY REGION, 2022–2029 (USD MILLION)
TABLE 33 AI IN BIOTECHNOLOGY MARKET FOR STRUCTURE-ACTIVITY RELATIONSHIP (SAR) MODELING, BY REGION, 2022–2029 (USD MILLION)
TABLE 34 AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
TABLE 35 AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY REGION, 2022–2029 (USD MILLION)
TABLE 36 AI IN BIOTECHNOLOGY MARKET FOR TRIAL DESIGN, BY REGION, 2022–2029 (USD MILLION)
TABLE 37 AI IN BIOTECHNOLOGY MARKET FOR SITE SELECTION, BY REGION, 2022–2029 (USD MILLION)
TABLE 38 AI IN BIOTECHNOLOGY MARKET FOR RECRUITMENT, BY REGION, 2022–2029 (USD MILLION)
TABLE 39 AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DATA ASSESSMENT, BY REGION, 2022–2029 (USD MILLION)
TABLE 40 AI IN BIOTECHNOLOGY MARKET FOR PREDICTIVE TOXICITY & RISK MONITORING, BY REGION, 2022–2029 (USD MILLION)
TABLE 41 AI IN BIOTECHNOLOGY MARKET FOR MONITORING & DRUG ADHERENCE, BY REGION, 2022–2029 (USD MILLION)
TABLE 42 AI IN BIOTECHNOLOGY MARKET FOR REAL-WORLD EVIDENCE (RWE) ANALYSIS, BY REGION, 2022–2029 (USD MILLION)
TABLE 43 AI IN BIOTECHNOLOGY MARKET FOR REGULATORY COMPLIANCE FUNCTIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 44 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 45 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 46 AI IN BIOTECHNOLOGY MARKET FOR SUPPLY CHAIN PLANNING, BY REGION, 2022–2029 (USD MILLION)
TABLE 47 AI IN BIOTECHNOLOGY MARKET FOR INVENTORY MANAGEMENT, BY REGION, 2022–2029 (USD MILLION)
TABLE 48 AI IN BIOTECHNOLOGY MARKET FOR LOGISTICS OPTIMIZATION, BY REGION, 2022–2029 (USD MILLION)
TABLE 49 AI IN BIOTECHNOLOGY MARKET FOR DEMAND FORECASTING, BY REGION, 2022–2029 (USD MILLION)
TABLE 50 AI IN BIOTECHNOLOGY MARKET FOR PREDICTIVE MAINTENANCE, BY REGION, 2022–2029 (USD MILLION)
TABLE 51 AI IN BIOTECHNOLOGY MARKET FOR OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 52 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 53 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 54 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH COORDINATION, BY REGION, 2022–2029 (USD MILLION)
TABLE 55 AI IN BIOTECHNOLOGY MARKET FOR PATIENT ENGAGEMENT, BY REGION, 2022–2029 (USD MILLION)
TABLE 56 AI IN BIOTECHNOLOGY MARKET FOR MARKETING OPERATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 57 AI IN BIOTECHNOLOGY MARKET FOR PREDICTIVE PRICING, BY REGION, 2022–2029 (USD MILLION)
TABLE 58 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 59 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 60 AI IN BIOTECHNOLOGY MARKET FOR MEDICATION ADHERENCE, BY REGION, 2022–2029 (USD MILLION)
TABLE 61 AI IN BIOTECHNOLOGY MARKET FOR ADVERSE EVENT REPORTING, BY REGION, 2022–2029 (USD MILLION)
TABLE 62 AI IN BIOTECHNOLOGY MARKET FOR PATIENT MONITORING, BY REGION, 2022–2029 (USD MILLION)
TABLE 63 AI IN BIOTECHNOLOGY MARKET FOR COMPLIANCE MONITORING, BY REGION, 2022–2029 (USD MILLION)
TABLE 64 AI IN BIOTECHNOLOGY MARKET FOR PATIENT SUPPORT PROGRAMS, BY REGION, 2022–2029 (USD MILLION)
TABLE 65 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 66 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 67 AI IN BIOTECHNOLOGY MARKET FOR RISK MANAGEMENT, BY REGION, 2022–2029 (USD MILLION)
TABLE 68 AI IN BIOTECHNOLOGY MARKET FOR COMPLIANCE MONITORING, BY REGION, 2022–2029 (USD MILLION)
TABLE 69 AI IN BIOTECHNOLOGY MARKET FOR SALES FORCE OPTIMIZATION, BY REGION, 2022–2029 (USD MILLION)
TABLE 70 AI IN BIOTECHNOLOGY MARKET FOR OTHER CORPORATE FUNCTIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 71 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
TABLE 72 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 73 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 74 AI IN BIOTECHNOLOGY MARKET FOR PUBLIC CLOUD, BY REGION, 2022–2029 (USD MILLION)
TABLE 75 AI IN BIOTECHNOLOGY MARKET FOR PRIVATE CLOUD, BY REGION, 2022–2029 (USD MILLION)
TABLE 76 AI IN BIOTECHNOLOGY MARKET FOR MULTI-CLOUD, BY REGION, 2022–2029 (USD MILLION)
TABLE 77 AI IN BIOTECHNOLOGY MARKET FOR HYBRID CLOUD, BY REGION, 2022–2029 (USD MILLION)
TABLE 78 AI IN BIOTECHNOLOGY MARKET FOR ON-PREMISE SOLUTIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 79 AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 80 AI IN BIOTECHNOLOGY MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 81 AI IN BIOTECHNOLOGY MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 82 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH INSTITUTES & LABS, BY REGION, 2022–2029 (USD MILLION)
TABLE 83 AI IN BIOTECHNOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2022–2029 (USD MILLION)
TABLE 84 AI IN BIOTECHNOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2022–2029 (USD MILLION)
TABLE 85 AI IN BIOTECHNOLOGY MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 86 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 87 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 88 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 89 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
TABLE 90 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 91 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 92 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
TABLE 93 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 94 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 95 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 96 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 97 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
TABLE 98 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 99 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 100 US: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 101 US: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 102 US: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
TABLE 103 US: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 104 US: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 105 US: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
TABLE 106 US: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 107 US: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 108 US: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 109 US: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 110 US: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
TABLE 111 US: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 112 US: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 113 CANADA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 114 CANADA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 115 CANADA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
TABLE 116 CANADA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 117 CANADA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 118 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
TABLE 119 CANADA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 120 CANADA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 121 CANADA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 122 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 123 CANADA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
TABLE 124 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 125 CANADA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 126 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 127 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 128 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 129 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
TABLE 130 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 131 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 132 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
TABLE 133 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 134 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 135 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 136 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 137 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
TABLE 138 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 139 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 140 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 141 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 142 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
TABLE 143 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 144 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 145 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
TABLE 146 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 147 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 148 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 149 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 150 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
TABLE 151 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 152 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 153 UK: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 154 UK: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 155 UK: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
TABLE 156 UK: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 157 UK: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 158 UK: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
TABLE 159 UK: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 160 UK: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 161 UK: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 162 UK: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 163 UK: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
TABLE 164 UK: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 165 UK: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 166 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 167 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 168 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
TABLE 169 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 170 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 171 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
TABLE 172 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 173 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 174 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 175 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 176 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
TABLE 177 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 178 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 179 ITALY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 180 ITALY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 181 ITALY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
TABLE 182 ITALY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 183 ITALY: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 184 ITALY: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
TABLE 185 ITALY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 186 ITALY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 187 ITALY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 188 ITALY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 189 ITALY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
TABLE 190 ITALY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 191 ITALY: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 192 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 193 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 194 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
TABLE 195 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 196 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 197 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
TABLE 198 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 199 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 200 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 201 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 202 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
TABLE 203 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 204 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 205 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 206 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 207 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
TABLE 208 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 209 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 210 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
TABLE 211 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 212 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 213 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 214 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 215 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
TABLE 216 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 217 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 218 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 219 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 220 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 221 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
TABLE 222 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 223 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 224 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
TABLE 225 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 226 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 227 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 228 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 229 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
TABLE 230 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 231 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 232 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 233 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 234 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
TABLE 235 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 236 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 237 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
TABLE 238 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 239 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 240 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 241 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 242 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
TABLE 243 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 244 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 245 CHINA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 246 CHINA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 247 CHINA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
TABLE 248 CHINA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 249 CHINA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 250 CHINA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
TABLE 251 CHINA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 252 CHINA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 253 CHINA: AI IN BIOTECHNOLOGY MARKET, BY POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 254 CHINA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 255 CHINA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
TABLE 256 CHINA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 257 CHINA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 258 INDIA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 259 INDIA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 260 INDIA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
TABLE 261 INDIA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 262 INDIA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 263 INDIA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
TABLE 264 INDIA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 265 INDIA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 266 INDIA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 267 INDIA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 268 INDIA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
TABLE 269 INDIA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 270 INDIA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 271 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 272 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 273 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
TABLE 274 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 275 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 276 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
TABLE 277 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 278 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 279 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 280 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 281 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
TABLE 282 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 283 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 284 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 285 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 286 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
TABLE 287 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 288 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 289 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
TABLE 290 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 291 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 292 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 293 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 294 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
TABLE 295 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 296 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 297 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 298 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 299 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 300 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
TABLE 301 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 302 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 303 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
TABLE 304 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 305 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 306 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 307 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 308 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE,2022–2029 (USD MILLION)
TABLE 309 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 310 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 311 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 312 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 313 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION,2022–2029 (USD MILLION)
TABLE 314 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 315 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 316 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
TABLE 317 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 318 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 319 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 320 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 321 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
TABLE 322 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 323 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 324 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 325 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 326 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
TABLE 327 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 328 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 329 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
TABLE 330 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 331 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 332 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 333 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 334 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
TABLE 335 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 336 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 337 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 338 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 339 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
TABLE 340 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 341 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 342 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
TABLE 343 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 344 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 345 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 346 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 347 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
TABLE 348 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 349 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 350 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 351 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 352 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 353 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
TABLE 354 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 355 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 356 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
TABLE 357 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 358 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 359 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE,2022–2029 (USD MILLION)
TABLE 360 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 361 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
TABLE 362 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 363 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 364 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 365 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 366 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
TABLE 367 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 368 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 369 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
TABLE 370 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 371 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 372 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 373 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 374 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
TABLE 375 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 376 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 377 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
TABLE 378 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022–2029 (USD MILLION)
TABLE 379 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022–2029 (USD MILLION)
TABLE 380 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 381 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2029 (USD MILLION)
TABLE 382 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022–2029 (USD MILLION)
TABLE 383 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 384 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 385 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 386 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 387 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022–2029 (USD MILLION)
TABLE 388 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS MODE, BY TYPE, 2022–2029 (USD MILLION)
TABLE 389 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 390 AI IN BIOTECHNOLOGY: DEGREE OF COMPETITION
TABLE 391 AI IN BIOTECHNOLOGY MARKET: OFFERING FOOTPRINT
TABLE 392 AI IN BIOTECHNOLOGY MARKET: FUNCTION FOOTPRINT
TABLE 393 AI IN BIOTECHNOLOGY MARKET: END-USER FOOTPRINT
TABLE 394 AI IN BIOTECHNOLOGY: REGION FOOTPRINT
TABLE 395 AI IN BIOTECHNOLOGY MARKET: DETAILED LIST OF KEY START-UPS/SMES
TABLE 396 AI IN BIOTECHNOLOGY: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
TABLE 397 AI IN BIOTECHNOLOGY MARKET: PRODUCT LAUNCHES & UPGRADES, JANUARY 2021–JANUARY 2025
TABLE 398 AI IN BIOTECHNOLOGY MARKET: DEALS, JANUARY 2021–JANUARY 2025
TABLE 399 AI IN BIOTECHNOLOGY MARKET: EXPANSIONS, JANUARY 2021–JANUARY 2025
TABLE 400 NVIDIA CORPORATION: COMPANY OVERVIEW
TABLE 401 NVIDIA CORPORATION: PRODUCTS OFFERED
TABLE 402 NVIDIA CORPORATION: PRODUCT LAUNCHES, JANUARY 2021−JANUARY 2025
TABLE 403 NVIDIA CORPORATION: DEALS, JANUARY 2021−JANUARY 2025
TABLE 404 ILLUMINA, INC.: COMPANY OVERVIEW
TABLE 405 ILLUMINA, INC.: PRODUCTS OFFERED
TABLE 406 ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2021−JANUARY 2025
TABLE 407 ILLUMINA, INC.: DEALS, JANUARY 2021−JANUARY 2025
TABLE 408 EXSCIENTIA: COMPANY OVERVIEW
TABLE 409 EXSCIENTIA: PRODUCTS OFFERED
TABLE 410 EXSCIENTIA: PRODUCT LAUNCHES, JANUARY 2021−JANUARY 2025
TABLE 411 EXSCIENTIA: DEALS, JANUARY 2021−JANUARY 2025
TABLE 412 EXSCIENTIA: OTHER DEVELOPMENTS, JANUARY 2021−JANUARY 2025
TABLE 413 SCHRÖDINGER, INC.: COMPANY OVERVIEW
TABLE 414 SCHRÖDINGER, INC.: PRODUCTS OFFERED
TABLE 415 SCHRÖDINGER, INC.: PRODUCT UPGRADES, JANUARY 2021−JANUARY 2025
TABLE 416 SCHRÖDINGER, INC.: DEALS, JANUARY 2021−JANUARY 2025
TABLE 417 RECURSION PHARMACEUTICALS, INC.: COMPANY OVERVIEW
TABLE 418 RECURSION PHARMACEUTICALS, INC.: PRODUCTS OFFERED
TABLE 419 RECURSION PHARMACEUTICALS, INC.: DEALS, JANUARY 2021−JANUARY 2025
TABLE 420 RECURSION PHARMACEUTICALS, INC.: EXPANSIONS, JANUARY 2021−JANUARY 2025
TABLE 421 RECURSION PHARMACEUTICALS, INC.: OTHER DEVELOPMENTS, JANUARY 2021−JANUARY 2025
TABLE 422 SOPHIA GENETICS: COMPANY OVERVIEW
TABLE 423 SOPHIA GENETICS: PRODUCTS OFFERED
TABLE 424 SOPHIA GENETICS: PRODUCT LAUNCHES, JANUARY 2021−JANUARY 2025
TABLE 425 SOPHIA GENETICS: DEALS, JANUARY 2021−JANUARY 2025
TABLE 426 PREDICTIVE ONCOLOGY: COMPANY OVERVIEW
TABLE 427 PREDICTIVE ONCOLOGY: PRODUCTS OFFERED
TABLE 428 PREDICTIVE ONCOLOGY: PRODUCT LAUNCHES, JANUARY 2021−JANUARY 2025
TABLE 429 PREDICTIVE ONCOLOGY: DEALS, JANUARY 2021−JANUARY 2025
TABLE 430 PREDICTIVE ONCOLOGY: EXPANSIONS, JANUARY 2021−JANUARY 2025
TABLE 431 BENEVOLENTAI: COMPANY OVERVIEW
TABLE 432 BENEVOLENTAI: PRODUCTS OFFERED
TABLE 433 BENEVOLENTAI: DEALS, JANUARY 2021−JANUARY 2025
TABLE 434 BENEVOLENTAI: OTHER DEVELOPMENTS, JANUARY 2021−JANUARY 2025
TABLE 435 EUROFINS DISCOVERY: COMPANY OVERVIEW
TABLE 436 EUROFINS DISCOVERY: PRODUCTS OFFERED
TABLE 437 EUROFINS DISCOVERY: PRODUCT LAUNCHES, JANUARY 2021−JANUARY 2025
TABLE 438 EUROFINS DISCOVERY: DEALS, JANUARY 2021−JANUARY 2025
TABLE 439 EUROFINS DISCOVERY: EXPANSIONS, JANUARY 2021−JANUARY 2025
TABLE 440 XTALPI INC.: COMPANY OVERVIEW
TABLE 441 XTALPI INC.: PRODUCTS OFFERED
TABLE 442 XTALPI INC.: DEALS, JANUARY 2021−JANUARY 2025
TABLE 443 DNANEXUS, INC.: COMPANY OVERVIEW
TABLE 444 DNANEXUS, INC.: PRODUCTS OFFERED
TABLE 445 DNANEXUS, INC.: DEALS, JANUARY 2021−JANUARY 2025
TABLE 446 DNANEXUS, INC.: OTHER DEVELOPMENTS, JANUARY 2021–JANUARY 2025
TABLE 447 NUMEDII, INC.: COMPANY OVERVIEW
TABLE 448 NUMEDII, INC.: PRODUCTS OFFERED
TABLE 449 BPGBIO, INC.: COMPANY OVERVIEW
TABLE 450 BPGBIO, INC.: PRODUCTS OFFERED
TABLE 451 BPGBIO, INC.: PRODUCT LAUNCHES, JANUARY 2021−JANUARY 2025
TABLE 452 BPGBIO, INC.: DEALS, JANUARY 2021−JANUARY 2025
TABLE 453 BPGBIO, INC.: OTHER DEVELOPMENTS, JANUARY 2021−JANUARY 2025
TABLE 454 IKTOS: COMPANY OVERVIEW
TABLE 455 IKTOS: PRODUCTS OFFERED
TABLE 456 IKTOS: DEALS, JANUARY 2021−JANUARY 2025
TABLE 457 IKTOS: OTHER DEVELOPMENTS, JANUARY 2021−JANUARY 2025
TABLE 458 INSILICO MEDICINE: COMPANY OVERVIEW
TABLE 459 INSILICO MEDICINE: PRODUCTS OFFERED
TABLE 460 INSILICO MEDICINE: PRODUCT APPROVALS, JANUARY 2021−JANUARY 2025
TABLE 461 INSILICO MEDICINE: DEALS, JANUARY 2021−JANUARY 2025
TABLE 462 INSILICO MEDICINE: OTHER DEVELOPMENTS, JANUARY 2021−JANUARY 2025
TABLE 463 LOGICA: COMPANY OVERVIEW
TABLE 464 LOGICA: PRODUCTS OFFERED
TABLE 465 LOGICA: PRODUCT LAUNCHES, JANUARY 2021−JANUARY 205
TABLE 466 AMERICAN CHEMICAL SOCIETY: COMPANY OVERVIEW
TABLE 467 AMERICAN CHEMICAL SOCIETY: PRODUCTS OFFERED
TABLE 468 AGANITHA AI INC.: COMPANY OVERVIEW
TABLE 469 AGANITHA AI INC.: PRODUCTS OFFERED
TABLE 470 AGANITHA AI INC.: DEALS, JANUARY 2021−JANUARY 2025
TABLE 471 AGANITHA AI INC.: OTHER DEVELOPMENTS, JANUARY 2021−JANUARY 2025

LIST OF FIGURES

FIGURE 1 AI IN BIOTECHNOLOGY MARKET SEGMENTATION & REGIONAL SCOPE
FIGURE 2 RESEARCH DESIGN
FIGURE 3 PRIMARY SOURCES
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
FIGURE 6 TOP-DOWN APPROACH
FIGURE 7 AI IN BIOTECHNOLOGY MARKET: CAGR PROJECTIONS
FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 9 DATA TRIANGULATION
FIGURE 10 AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION)
FIGURE 11 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2024 VS. 2029 (USD MILLION)
FIGURE 12 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2024 VS. 2029 (USD MILLION)
FIGURE 13 AI IN BIOTECHNOLOGY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 14 AI IN BIOTECHNOLOGY MARKET: GEOGRAPHICAL SNAPSHOT
FIGURE 15 GROWING FOCUS ON COST-EFFECTIVE PROCESSES AND FAVORABLE GOVERNMENT SUPPORT AND FUNDING TO DRIVE MARKET
FIGURE 16 NORTH AMERICA TO DOMINATE AI IN BIOTECHNOLOGY MARKET DURING FORECAST PERIOD
FIGURE 17 PHARMACEUTICAL COMPANIES IN NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
FIGURE 18 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 19 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
FIGURE 20 AI IN BIOTECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 21 AI IN BIOTECHNOLOGY MARKET: ECOSYSTEM ANALYSIS
FIGURE 22 AI IN BIOTECHNOLOGY MARKET: VALUE CHAIN ANALYSIS
FIGURE 23 AI IN BIOTECHNOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 24 PATENT PUBLICATION TRENDS IN AI IN BIOTECHNOLOGY MARKET, 2015–2024
FIGURE 25 PATENT ANALYSIS OF AI IN BIOTECHNOLOGY MARKET, JANUARY 2015–JANUARY 2025
FIGURE 26 EVOLUTION OF AI IN BIOTECHNOLOGY MARKET
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS
FIGURE 28 KEY BUYING CRITERIA FOR TOP 3 END USERS
FIGURE 29 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 30 AI IN BIOTECHNOLOGY MARKET: INVESTMENT & FUNDING SCENARIO
FIGURE 31 MARKET POTENTIAL OF AI/GENERATIVE AI ON AI IN BIOTECHNOLOGY SOLUTIONS
FIGURE 32 NUMBER OF AI-DISCOVERED MOLECULES IN CLINICAL TRIALS
FIGURE 33 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET SNAPSHOT
FIGURE 34 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET SNAPSHOT
FIGURE 35 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET, BETWEEN JANUARY 2021 AND JANUARY 2025
FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET, 2019–2023 (USD BILLION)
FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET (2023)
FIGURE 38 RANKING OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET, 2023
FIGURE 39 AI IN BIOTECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
FIGURE 40 AI IN BIOTECHNOLOGY MARKET: COMPANY FOOTPRINT
FIGURE 41 AI IN BIOTECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
FIGURE 42 EV/EBITDA OF KEY VENDORS
FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF AI IN BIOTECHNOLOGY SOLUTION VENDORS
FIGURE 44 AI IN BIOTECHNOLOGY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 45 NVIDIA CORPORATION: COMPANY SNAPSHOT (2024)
FIGURE 46 ILLUMINA, INC.: COMPANY SNAPSHOT (2023)
FIGURE 47 EXSCIENTIA: COMPANY SNAPSHOT (2023)
FIGURE 48 SCHRÖDINGER, INC.: COMPANY SNAPSHOT (2023)
FIGURE 49 RECURSION PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2023)
FIGURE 50 SOPHIA GENETICS: COMPANY SNAPSHOT (2023)
FIGURE 51 PREDICTIVE ONCOLOGY: COMPANY SNAPSHOT (2023)
FIGURE 52 BENEVOLENTAI: COMPANY SNAPSHOT (2023)
FIGURE 53 EUROFINS DISCOVERY: COMPANY SNAPSHOT (2023)
FIGURE 54 XTALPI INC.: COMPANY SNAPSHOT (2023)

Methodology

This market research study primarily relied on secondary sources, directories, and databases to collect information for this technical, market-oriented, and financial analysis of the AI in biotechnology market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives from major market players, and industry consultants, among others, to gather and verify critical qualitative and quantitative data and assess market prospects. The size of the AI in biotechnology market was estimated using multiple secondary research methods and confirmed with inputs from primary research to determine the final market size.

Secondary Research

The secondary research process involved extensively using secondary sources, including directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the World Health Organization (WHO), the Organization for Economic Co-operation and Development (OECD), Healthcare Information and Management Systems Society (HIMSS), Centers for Disease Control and Prevention (CDC), ClinicalTrials.gov, expert interviews, and MarketsandMarkets analysis.

Secondary research was conducted to gather information for the detailed, technical, market-focused, and commercial analysis of the AI in biotechnology market. It was also used to collect key information about major players, market classification, and segmentation based on industry trends, down to the most detailed level, along with significant developments related to market and technology perspectives. Additionally, a database of leading industry players was compiled using secondary research.

Primary Research

During the primary research process, various sources from both the supply and demand sides were interviewed to gather qualitative and quantitative information for this report. Primary sources mainly include industry experts from core and related industries, preferred suppliers, manufacturers, distributors, technology developers, researchers, and organizations involved in all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, such as key industry participants, subject-matter experts (SMEs), C-level executives of leading market players, and industry consultants, among other specialists, to obtain and verify critical qualitative and quantitative information as well as assess prospects.

Primary research was conducted to identify segmentation types, industry trends, key players, and key market dynamics such as drivers, restraints, opportunities, challenges, and strategies adopted by key players.

After completing the market engineering process- which includes calculations for market statistics, market breakdown, size estimations, forecasting, and data triangulation- extensive primary research was carried out. This research aimed to gather information and verify the key numbers obtained during the market analysis. Additionally, primary research was used to identify different types of market segmentation, analyze industry trends, evaluate the competitive landscape of AI solutions for biotechnology offered by various players, and understand key market dynamics such as drivers, restraints, opportunities, challenges, industry trends, and strategies employed by key market players.

In the complete market engineering process, the top-down and bottom-up approaches, along with several data triangulation methods, were extensively used to estimate and forecast the market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was conducted on the entire market engineering process to identify key information and insights throughout the report.

Breakdown of Primary Interviews

Note 1: Others include sales, marketing, and product managers.

Note 2: Tiers are defined based on a company’s total revenue, as of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The market size estimates and forecasts in this study are based on a combination of the bottom-up approach (revenue share analysis of leading players) and the top-down approach (evaluation of utilization, adoption, and penetration trends by offering, function, deployment mode, end user, and region).

Data Triangulation

After determining the overall market size from the estimation process described above, the market for AI in biotechnology was divided into various segments and subsegments. To finalize the overall market analysis and obtain accurate statistics for all segments and subsegments, data triangulation and market breakdown techniques were used whenever applicable. The data was cross-verified by examining different factors and trends from both the demand and supply sides of the market for AI in biotechnology.

Market Definition

The AI in biotechnology market includes technologies that use artificial intelligence to advance drug discovery, genomics, and personalized medicine. This market is defined by the growing utilization of machine learning and data analytics to improve research and development efficiency.

Stakeholders

Healthcare IT service providers
Pharmaceutical/Biopharmaceutical companies
Biotechnology firms
AI technology providers
Academic & research institutions
Academic medical centers/universities/hospitals
Regulatory agencies
Clinical research organizations (CROs)
Genomic testing labs
Government agencies
Startups in AI and biotech
Pharmaceutical supply chain partners
Consulting firms
Clinical trial management system providers
Bioinformatics companies
Advocacy groups
Investors & financial institutions

Report Objectives

To define, describe, and forecast the AI in biotechnology market by offering, function, deployment mode, end user, and region
To provide detailed information regarding the major drivers, restraints, opportunities, and challenges influencing market growth
To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall AI in biotechnology market
To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
To forecast the size of the AI in biotechnology market in five main regions (and their respective countries): North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America
To provide key industry insights, such as value chain, regulatory, patent, and recession impact analysis
To profile the key players in the market and comprehensively analyze their core competencies
To track and analyze competitive developments, such as product launches & upgrades, collaborations, partnerships, acquisitions, investments, contracts, agreements, alliances, mergers, funding, and expansions of the leading players in the market
To benchmark players within the market using the company evaluation matrix, which analyzes market players on various parameters within the broad categories of business strategy, market share, and product offering

AI in Biotechnology Market by Function (Drug Design & Optimization, Biomarker, SAR; Clinical Trial Design, Data Assessment, RWE, Inventory, Supply Chain, Logistics; Launch, Pricing, Patient Engagement, Adverse Events) and End User - Global Forecast to 2035

OVERVIEW

KEY TAKEAWAYS

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

MARKET DYNAMICS

Driver: Rising adoption of AI in precision medicine

Restraint: High implementation costs of AI limit adoption in biotechnology, especially for SMEs and emerging economies

Opportunity: Surge in biotechnology investments enhances opportunities for AI to accelerate drug discovery innovations

Challenge: Data quality and interpretability issues that hinder AI integration and trustworthiness

AI in Biotechnology Market: COMMERCIAL USE CASES ACROSS INDUSTRIES

MARKET ECOSYSTEM

MARKET SEGMENTS

AI in Biotechnology Market, by Offering

AI in Biotechnology Market, by Function

AI in Biotechnology Market, by Deployment Mode

AI in Biotechnology Market, by End User

REGION

Asia Pacific to be fastest-growing region in global AI in biotechnology market during forecast period

AI in Biotechnology Market: COMPANY EVALUATION MATRIX

KEY MARKET PLAYERS

MARKET SCOPE

WHAT IS IN IT FOR YOU: AI in Biotechnology Market REPORT CONTENT GUIDE

DELIVERED CUSTOMIZATIONS

RECENT DEVELOPMENTS

Table of Contents

Methodology

Secondary Research

Primary Research

Market Size Estimation

Data Triangulation

Market Definition

Stakeholders

Report Objectives

TABLE OF CONTENTS

METHODOLOGY

Personalize This Research

Let Us Help You

Growth opportunities and latent adjacency in AI in Biotechnology Market